Rich Pilnik

Chairman of the Board, DiaMedica Therapeutics Inc.

Richard D. Pilnik is an experienced healthcare/pharmaceutical executive, native of São Paulo, Brazil, with an international 35+ year career with posts as Chairman, CEO, and senior operational roles as Chief Marketing Officer; President of Europe, Middle-East, Africa and Russia; President for Latin America; General Manager Mexico and various management positions in Brazil, Venezuela, UK and USA.
Rich currently serves as Chairman of the Board of DiaMedica, Inc. (NASDAQ:DMAC) a clinical stage biopharmaceutical company and a past Chairman of Chiltern International, a (CRO) Clinical Research Organization, until its sale to Covance (Q2 2017). In June 2014 he retired from Quintiles Transnational (NYSE: IQVIA) as Executive Vice President and President of Global Commercial Solutions. Prior to that, Rich served as Group Vice President and Chief Marketing Officer for Eli Lilly and Company (NYSE: LLY) retiring in 2008 after a 25 year career.
Rich earned a bachelor's degree in economics from Duke University in 1979 and an MBA in marketing and strategic planning from Kellogg School of Management at Northwestern University in 1983.
In addition to DiaMedica, he currently sits on the Boards of Bial (largest Portuguese pharmaceutical company); WIRB Copernicus (WCG) (20 of the clinical research industry’s most respected and innovative service companies) and an Emeritus Board Member of The Fuqua School of Business at Duke University. He is also a strategy coach and mentor to young healthcare entrepreneurs located in various parts of the world
Previously he served on the Board of Certara, a drug development and data analytics company under Arsenal Capital Partners (sold to EQT private equity); Elan Biopharmaceuticals (NYSE: ELN) until the acquisition by Perrigo (NYSE: PRGO).
He is a past member of the Indiana Cross Roads Council for the Boy Scouts of America. He is past Chairman of the (PhRMA) Pharmaceutical Research Manufacturers Association's Latin America Committee; the PhRMA European Executive Committee and member of the Council of America's Advisory Board.